Key result
The soluble urokinase plasminogen activator receptor (suPAR) is a promising inflammatory biomarker that could potentially improve the prediction of disease severity and mortality across several conditions.
Answers are grounded in this paper and cite their sources.
Inflammation is a key player in the development of an increasing amount of diseases. The soluble urokinase plasminogen activator receptor (suPAR) is a highly flexible molecule with intrinsic chemotactic properties. This glycoprotein has been evaluated as a biomarker of inflammation, immune activation, organ damage and clinical outcome in several pathologies, including cardiovascular disease, hepatitis, renal disorders and rheumatic pathologies. The use of this early warning inflammatory biomarker could potentially improve the prediction of the severity of these diseases and mortality. In the present paper, we describe the general characteristics of suPAR and its intriguing role as a biomarker in different inflammatory diseases.
No takes yet. Share an insight, caveat, or question.
Desmedt et al. (2017) conducted a review in Inflammatory diseases. Soluble urokinase plasminogen activator receptor (suPAR) was evaluated. The soluble urokinase plasminogen activator receptor (suPAR) is a promising inflammatory biomarker that could potentially improve the prediction of disease severity and mortality across several conditions.
Synapse has enriched 10 related papers. Consider them for comparative context: